We have examined the ability of mice with severe combined immunodeficiency (SCID mice) reconstituted with human peripheral blood mononuclear cells (PBMC) These findings are also consistent with a requirement for persistence of antigen for the maintenance of B-cell memory. The ability to achieve specific human antibody levels equivalent to those obtained with humans indicates that reconstituted mice may be useful for the evaluation of human antibody-mediated mechanisms of resistance to infection. The data indicate, however, that cells from immunized donors will have to be used for such studies.
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CB.17 scid/scid mice (SCID mice) lack functional B and T lymphocytes and therefore are unable to reject allogeneic and xenogeneic tissue grafts (1) . Two groups of investigators have demonstrated that human lymphocytes can be transferred into these mice, with resultant spontaneous production of human immunoglobulin (Ig). In one of these models (the SCID/Hu mouse model), the mice are reconstituted with human fetal liver, thymus, and lymph nodes (5) . In the other, the Hu-PBL/SCID mouse model, the mice are reconstituted by intraperitoneal (i.p.) transplantation of human peripheral blood mononuclear cells (PBMC) (6) . In both the Hu-PBL/ SCID and SCID/Hu mouse models, circulating human Ig can be detected within a few weeks of transplantation of human cells or tissues. In the case of the Hu-PBL/SCID mice, specific antibody responses to tetanus toxoid (7TI) immunization have also been demonstrated (6) .
Much of the interest in reconstituted SCID mice derives from their potential use for studying immunoprophylactic and therapeutic treatments of cells infected with human immunodeficiency virus. Since human lymphocytes survive and function in the mice for periods of several months (6) , the mice potentially provide a practical alternative to studies with primates, which are more expensive and much less accessible. washed, and p-nitrophenylphosphate substrate in diethanolamine buffer (pH 9.8) was added. After incubation for 30 min in the dark at room temperature, 3 M sodium hydroxide was added to each well and the plates were read at 405 nm. The titers of antibody in the donors and the mice are expressed as the reciprocal of the highest dilution at which optical density values above background were observed. Because no individuals who had not been immunized against TT could be identified, control wells for the human sera obtained directly from the human subjects were simply microwells to which no experimental sera were added. Control wells for measurement of human antibody in sera from Hu-PBL/SCID mice contained normal mouse serum. Human sera for titers of preexisting antibody in the donors were obtained at the time that the PBMC were obtained for reconstitution of the mice. For some studies, quantities of specific antibody were determined by comparing optical density readings of the experimental sample with those generated by standard curves of human Ig run in the same assay.
Human subjects. Fifty to 200 ml of human peripheral blood was obtained from subjects before and after immunization with TT (10 Lf units in 0.5 ml) or KLH (100 ,ug) adsorbed to aluminum phosphate, administered intramuscularly. Immunizations and phlebotomy for reconstitution of SCID mice were approved by institutional human studies review committees. Adoptive transfer of secondary responses to TT was consistently observed. The magnitude of this response was highly dependent on the immunization protocol ( Table 2 ). Mice that were reconstituted with cells from the donor prior to booster immunization of the donor and that received no immunization had barely detectable specific human anti-TT responses. Similarly, reconstituted mice that were immunized 3 days after engraftment with human cells had a response that was 20-fold higher than that observed with unimmunized, reconstituted mice. However, the specific human antibody levels achieved with the mice were still more than 1 log unit less than those circulating in the human donor. Waiting until 35 days after human cell reconstitution to give the IT booster immunization to the reconstituted mice resulted in a loss of effect of the booster immunization, suggesting a loss of the memory B cells producing anti-IT antibody.
Use of cells from the same human donor which were obtained 10 days after donor immunization resulted in a marked enhancement of the specific antibody responses that could be obtained with reconstituted SCID mice. At the time that cells were obtained from the donor, the donor had a reciprocal antibody titer of 49,000. By giving the mice booster immunizations of IT 3 days after cell transfer a reciprocal antibody titer of 30,064 was obtained with mice, a level essentially equivalent to that observed with the human donor. This level of antibody was effectively maintained for 45 days, the last time point examined. Again, waiting until 35 days after transplantation of human cells into the mice to provide the booster immunization of the mice resulted in a significant reduction in the magnitude of the human antibody response observed compared with the response of mice given booster immunizations 3 days posttransplantation.
Induction of human IgA and IgM antibodies by secondary immunization of Hu-PBL/SCID mice receiving PBMC from TT-primed donors. To further characterize the secondary antibody response in Hu-PBL/SCID mice, mice were reconstituted with cells from IT-immune donors other than those described above, and quantitative levels of total IT-specific Ig and specific IgA and IgM antibody levels were determined. The time of IT immunization of these donors was not known beyond the fact that they were not recently immunized, and their immune status was therefore reflected in their preexisting IT-specific antibody levels. None of the three subjects used for these studies had preexisting anti- DISCUSSION These studies were designed to characterize the ability of Hu-PBL/SCID mice to generate human antibody responses. We initially examined the response to an antigen to which most humans are not immune, KLH. SCID mice reconstituted with cells from nonimmune individuals were unable to produce any detectable specific antibody response, even when recipient mice were given booster immunizations within 3 days of cell transfer. Mice reconstituted with cells from an individual who had been immunized with KLH 18 months earlier attained, after in vivo booster immunization of the mice, levels of circulating specific human IgG that exceeded those of the donor of the human cells (Table 1) . However, mice that received cells from a KLH-nonimmune donor failed to generate any KLH-specific antibody upon immunization.
Similarly, mice reconstituted with PBMC from an individual whose last immunization against TT had occurred more than 10 years previously had a minimal anti-IT response (Table 2) . After the donor, whose IT immunization status had declined over 10 years, was given a booster immunization, mice reconstituted with his cells and immunized in vivo were able to generate an anti-TT response that yielded levels of circulating specific antibody approaching those observed with the human donor ( At least two possible explanations for the failure of reconstituted SCID mice to develop primary human antibody responses could be proposed, and both are related to a deficiency in critical cells required for the generation of an antigen-specific response. It should be emphasized that the cells being placed in the mice are derived from peripheral blood. Therefore, the ability to generate a specific response is going to depend on the number of antigen-specific circulating lymphocytes. This number is likely to be higher in recently immunized individuals than in individuals who were immunized in the past (2) .
The ability of mice to generate an antibody response might also be related to the presence in the peripheral blood of a number of antigen-presenting cells sufficient to activate the helper T cells involved in the response to either KLH or TT, both of which are T-cell-dependent antigens (3, 7) . The available data indicate that macrophages survive less well in PBMC-reconstituted SCID mice than do lymphocytes (6) . If sufficient antigen-specific B cells were present in the transplanted cells, these cells might function as antigen-presenting cells, obviating the need for macrophages. Nonimmune donors would lack such a pool of expanded antigen-specific B cells and would therefore be more dependent for the activation of helper T cells on the presence of other antigenpresenting cells. Thus, the generation by primary or secondary immunization of circulating specific B cells in the peripheral blood of the human cell donor might be essential for both generation of T-cell help and for actual antibody production.
The requirement for in vivo boosting within a short time period after cell transfer suggests that the failure to stimulate the specifically reactive clones results in the loss of the ability to generate secondary responses as well. This rapid disappearance of immune response capability is unlikely to represent a general loss of human cells from reconstituted mice, as immunized mice continue to produce human antibody for a period of at least several months (6 and unpublished observations). However, this observation may reflect preferential loss of memory cells in these mice. The maintenance of clones of a given specificity appears to require stimulation of that clone at a time when specific responsive cells are most abundant. This finding is consistent with the observations of others, indicating that the presence of continuous antigenic stimulus is required for persistence of memory B cells (8) , although a loss of specific helper T cells in this setting cannot be excluded.
Mazingue et al. (4) have recently reported the obtainment of primary immune responses to schistosome antigens in SCID mice reconstituted with PBMC from a healthy donor. While this donor was free of schistosomiasis, the authors provided no evidence that the healthy donor had no preexisting immunity to the schistosome antigens, which could have been elicited by exposure to a cross-reacting antigen. Thus, it is unclear that the response obtained with the mice was truly primary. The investigators also employed complete Freund's adjuvant in their immunization protocol, which might be an alternative explanation for their ability to elicit primary responses. Since the mice in the study by Mazingue et al. were reconstituted with only 5 x 106 to 10 x 106 human PBMC, however, it seems unlikely that the unprimed donor would contain enough circulating precursors to reconstitute a detectable specific response in the mice.
Because it is difficult to recover human cells from reconstituted mice sufficient to perform in vitro assays of effector T-cell responses, we have not evaluated functions such as cytotoxic T-cell activity, mediated by CD8+ T cells, in reconstituted SCID mice. However, as indicated, antibody responses to the antigens being studied are known to require the activity of CD4+ helper T cells, and the presence of such responses is indicative of helper T-cell as well as B-cell functions.
These studies indicate that reconstituted SCID mice could prove to be useful for the evaluation of candidate vaccines designed to elicit protective humoral immune responses, but only under defined conditions. The cells used to reconstitute the mice must be obtained from individuals who have already been vaccinated. In addition, optimization of the human antibody response requires early booster immunization of the reconstituted mice. The ability to challenge such mice will be particularly useful in evaluating the protective efficacy of vaccines against pathogens, such as human immunodeficiency virus, which could not be used in human clinical trials.
